Bliss GVS Pharma Ltd.

View in App
136.30 +6.75 ▲5.2%

08 December 2023, 04:01:00 PM
Volume: 20,295

Company Profile

View details >>
Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.blissgvs.com
Market Cap 1,424.07 Cr.
Enterprise Value(EV) 1,348.32 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 8.43 Trailing Twelve Months Ending 2023-09
Price-Earning Ratio (PE) 16.13 Trailing Twelve Months Ending 2023-09
Industry PE 38.52 Trailing Twelve Months Ending 2023-09
Book Value / Share 88.96 Trailing Twelve Months Ending 2023-09
Price to Book Value 1.53 Calculated using Price: 136.05
Dividend Yield 0.37 Period Ending 2023-03
No. of Shares Subscribed 10.47 Cr. 104,672,822 Shares
FaceValue 1
About Bliss GVS Pharma Ltd.
It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company's most unique product is ‘Today Vaginal Contraceptive', a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Bliss GVS Pharma Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Bliss GVS Pharma Ltd. Performance

View details >>
1 Day
+5.21%
1 Week
-3.52%
1 Month
+20.81%
3 Month
+39.18%
6 Month
+80.34%
1 Year
+84.56%
2 Year
+35.42%
5 Year
-2.71%
10 Year
+254.95%

Bliss GVS Pharma Ltd. Fundamental Ratios

View details >>
9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 19.74 26.73 25.06 17.34 21.43 13.79 9.64 2.88 9.11
Return on Capital Employed (%) 23.57 32.07 31.06 24.61 26.58 17.02 12.49 6.37 12.22
Return on Assets (%) 9.01 13.04 11.88 9.42 14.35 9.86 7.03 2.12 6.78

Bliss GVS Pharma Ltd. Balance Sheet

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 337 413 487 536 646 736 808 819 884 930
Non Curr. Liab. 68 50 33 13 38 46 45 29 43 62
Curr. Liab. 243 379 437 299 207 231 204 233 193 172
Minority Int. 15 33 66 11 14 15 20 28 34 33
Equity & Liab. 662 874 1,023 860 905 1,027 1,077 1,109 1,154 1,197
Non Curr. Assets 245 291 457 170 211 257 312 332 456 451
Curr. Assets 417 583 566 690 693 770 765 777 697 747
Misc. Exp. not W/O 0
Total Assets 662 874 1,023 860 905 1,027 1,077 1,109 1,154 1,197

Bliss GVS Pharma Ltd. Profit and Loss

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09 Rs. Cr. TTM
Net Sales 407 547 798 815 899 689 577 747 752 762
Other Income 20 24 13 27 38 39 22 31 18 26
Total Income 427 571 811 841 936 728 599 779 769 788
Total Expenditure -304 -391 -596 -618 -741 -566 -471 -629 -634 -629
PBIDT 124 180 215 224 195 163 129 150 135 159
Interest -16 -19 -20 -23 -4 -8 -7 -5 -10 -9
Depreciation -11 -13 -20 -21 -9 -13 -17 -17 -19 -22
Taxation -35 -48 -63 -57 -55 -34 -30 -31 -29 -37
Exceptional Items -34 -13 -74
PAT 61 100 113 89 127 95 74 23 77 91
Minority Interest -1 -18 -31 -30 -3 2 -5 -8 -6 -2
Share Associate
Other Related Items
Consolidated Net Profit 60 82 82 59 124 97 68 15 71 88
Adjusted EPS 6 8 8 6 12 9 7 1 7 8

Bliss GVS Pharma Ltd. Cash Flow

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 41 38 113 289 18 40 47 64 135 34
Cash Fr. Inv. -11 -29 -50 -231 50 -74 -48 -47 -93 -8
Cash Fr. Finan. -8 -42 -40 -10 -76 17 -6 -21 -24 -25
Net Change 22 -33 23 48 -8 -17 -8 -4 19 2
Cash & Cash Eqvt 50 5 28 47 37 15 15 13 22 25

Bliss GVS Pharma Ltd. Shareholding Pattern

View details >>
9 Qtrs 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%)
Promoter 33.19 33.14 33.14 34.51 34.55 34.46 35.04 35.12 35.06
Public 66.81 66.86 66.86 65.49 65.45 65.54 64.96 64.88 64.94
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Bliss GVS Pharma Ltd. Announcements

View details >>
Fri, 03 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the copies of newspaper advertisement published regarding extract of the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2023 "The Economic Times & The Free Press Journal" an English Daily and "Maharashtra Times & Navshakti" a Regional Daily on November 03 2023.
Wed, 01 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday November 01 2023
We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday November 01 2023 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Board has considered and approved the following matters amongst others:1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2023. 2. Investment of INR 30 Crores (Approx.) for Capacity Addition/Inclusion of Semi-Solids Finished formulation at our Palghar Vevoor Unit. The Total Capacity expected is approx. 200 million Units in Semi-Solids Dosage and that is expected to be completed and available for commercial production by end of F. Y 2025-26. This expansion shall be funded by a combination of debt and internal accrual.
Wed, 01 Nov 2023
Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2023
We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday November 01 2023 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI Listing Regulations. Enclosed herewith Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2023 along with Limited Review Report.

Bliss GVS Pharma Ltd. Technical Scans

View details >>
Fri, 08 Dec 2023
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Below Last Week Low Close Below Last Week Low
High Increase in 1 Month High Increase in 1 Month
High Increase in 3 Months High Increase in 3 Months
High Increase in 6 Months High Increase in 6 Months

Bliss GVS Pharma Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 296,437.84 1,235.50 -0.3%
Cipla Ltd. 98,444.27 1,218.85 -0.3%
Divi's Laboratories Ltd. 97,728.28 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. 96,135.30 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. 79,790.42 5,542.00 +1.5%
Mankind Pharma Ltd. 78,250.95 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. 69,508.23 2,056.00 -2.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-09 34.68 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-09 28.51 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-09 73.38 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-09 18.88 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-09 114.40 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 61.04 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-09 52.11 2,056.00 -2.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-09 4.96 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-09 3.97 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-09 7.71 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-09 3.77 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-09 12.27 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 9.28 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-09 10.36 2,056.00 -2.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 0.02 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,056.00 -2.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,056.00 -2.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,056.00 -2.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,056.00 -2.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,056.00 -2.2%

Bliss GVS Pharma Ltd. FAQ's

What is Bliss GVS Pharma share price?
Can I buy Bliss GVS Pharma shares now?
What is the Dividend Yield of Bliss GVS Pharma?
What is the Market Cap of Bliss GVS Pharma?
What are the key metrics to analyse Bliss GVS Pharma?
What is the 52 Week High and Low of Bliss GVS Pharma?
What is the trend of Bliss GVS Pharma share price?